Smart dosing of antibiotics may cut infection risk after colon surgery
NCT ID NCT05253339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the antibiotic cefoxitin using a target-controlled infusion pump works better than the standard method to prevent surgical site infections in patients having colon or rectal surgery. About 2,500 adults took part. The goal was to see if the new method lowers infection rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cefoxitin
- What this could lead to
- If successful, this could show that target-controlled infusion reduces surgical site infections better than the standard method.
- What could go wrong
- This is a completed single-center trial; results may not apply to other hospitals or surgeries. The benefit over standard dosing may be small or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-BACTERIAL AGENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, Songpa-Gu,, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- First human trial launches for Hemay5259: a new Extended-Release drug candidate
- Apples' hidden power: study probes how polyphenols scavenge harmful carbonyls
- New vaginal capsule aims to tackle stubborn bacterial vaginosis
- New painkiller injection could cut opioid use after chest surgery